IDEXX Laboratories (IDXX) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
IDEXX Laboratories (IDXX) has outperformed QuidelOrtho (QDEL) over the past year, losing 17.6% versus a loss of 52.2%. Over five years, IDXX leads with a -18.4% price change compared with -89.5% for QDEL. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $920.3 million), about 44.3 times the size.
On valuation, QuidelOrtho trades at a lower forward P/E (9.3x vs 30.9x for IDEXX Laboratories). IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus -41.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | QDEL |
|---|---|---|
| Share price | $518.00 | $13.42 |
| Market cap | $40.81B | $920.28M |
| 1-day change | +0.95% | +8.14% |
| YTD return | -23.43% | -53.01% |
| 1-year return | -17.61% | -52.17% |
| 5-year return | -18.44% | -89.54% |
| P/E ratio (TTM) | 36.40 | — |
| Forward P/E | 30.95 | 9.31 |
| EPS (TTM) | $14.23 | $-16.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | $2.73B |
| Revenue growth (YoY) | +10.42% | -1.89% |
| Net income (latest FY) | $1.06B | $-1.13B |
| Gross margin | 61.80% | 46.67% |
| Operating margin | 31.60% | -33.67% |
| Net margin | 24.62% | -41.45% |
| 52-week high | $769.98 | $35.58 |
| 52-week low | $500.61 | $9.92 |
| Distance from 52-week high | -32.73% | -62.28% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +35.39% | +9.31% |
| Average volume | 551.68K | 1.55M |
| Shares outstanding | 78.78M | 68.58M |
| Employees | 11,000 | 6,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 44.3 times larger than QuidelOrtho by market value ($40.81B vs $920.28M).
- IDXX has outperformed QDEL by 34.6 percentage points over the past year.
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus -41.5 cents for QuidelOrtho.
- IDEXX Laboratories grew revenue faster in its latest fiscal year (+10.42% vs -1.89%).
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
IDXX vs QDEL FAQ
Which is bigger, IDEXX Laboratories or QuidelOrtho?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $920.28M for QuidelOrtho (QDEL).
Which stock has performed better over the past year, IDXX or QDEL?
IDXX returned -17.61% over the past 12 months, compared with -52.17% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and QuidelOrtho in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.